Welcome to our dedicated page for USANA HEALTH SCIENCES SEC filings (Ticker: USNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
USANA Health Sciences, Inc. filings document financial results, management commentary and Regulation FD disclosures for a health and wellness products company. Form 8-K reports cover quarterly and annual results, preliminary sales information, guidance, exhibits and conference-call materials tied to the company’s operating updates.
Proxy and governance filings address director elections, board matters, executive compensation, equity awards and pay-versus-performance disclosure. Other material-event reports document leadership changes, transition agreements and compensatory arrangements, providing formal records of governance and management structure for USANA Health Sciences.
USANA Health Sciences Chief Commercial Officer Brent Neidig reported multiple stock transactions over three days in February 2026 related to vested restricted stock units (RSUs). On February 6, 2026, 2,219 RSUs were converted into common stock, with 1,102 common shares disposed of at $21.34 per share, leaving 1,117 common shares directly held after that date.
On February 7, 2026, a further 1,401 RSUs were converted into common stock, with 696 common shares disposed of at $21.34 per share, resulting in 1,822 directly held common shares. On February 8, 2026, 3,690 RSUs were converted, with 1,753 common shares disposed of at $21.34 per share and 3,759 common shares directly held afterward.
Following these transactions, Neidig directly held 3,759 shares of common stock and 36,584 RSUs. Each RSU represents a contingent right to receive one share of USANA common stock, and the RSUs vest in 25% increments on the anniversaries of February 6, 2023, February 7, 2022, and February 8, 2024, as applicable.
USANA Health Sciences chief people officer Paul A. Jones reported several equity compensation transactions in early February 2026. On February 6, 7 and 8, 2026, restricted stock units converted into common stock in amounts of 2,174, 1,372 and 2,514 shares at an exercise price of $0 per share.
On each of those dates, portions of common stock were disposed of in transactions coded "F" in amounts of 754, 476 and 872 shares at a price of $21.34 per share. Following these transactions, Jones directly owned 9,127 shares of USANA common stock and 25,585 restricted stock units, each RSU representing a contingent right to receive one share as they vest on specified anniversary dates.
USANA Health Sciences Chief Financial Officer Doug G. Iie kking reported multiple equity transactions over February 6–8, 2026. On each date, restricted stock units were exercised for 3,532, 2,231, and 4,084 shares of common stock, respectively, at an exercise price of $0 per share.
Related dispositions of common stock at $21.34 per share totaled 2,567, 1,612, and 2,746 shares on the same dates. Following these transactions, the officer directly held 2,922 shares of common stock and 41,579 restricted stock units, each representing the right to receive one share of USNA common stock.
USANA Health Sciences’ chief legal officer, Joshua Foukas, reported multiple equity compensation transactions. On February 6–8, 2026, restricted stock units (RSUs) covering 3,111, 1,571, and 3,597 units were converted into the same number of USANA common shares at an exercise price of $0 per share.
Across the same dates, Foukas disposed of 1,483, 749, and 1,586 common shares at $21.34 per share. Following these transactions, he directly held 4,461 common shares and 36,608 RSUs. Each RSU represents a right to one share and vests 25% annually on specified February anniversaries.
USANA Health Sciences CEO and Executive Chairman Kevin Guest reported equity award activity over three days in February 2026. On February 6, 7, and 8, 2026, restricted stock units vested and were converted into 12,061, 6,601, and 4,425 shares of USANA common stock, respectively, at an exercise price of $0 per unit.
On each vesting date, a portion of the newly issued shares—5,345, 2,796, and 1,875 shares—was withheld at $21.34 per share to cover tax obligations, reflected with transaction code “F.” After these transactions, Guest directly beneficially owned 40,853 shares of common stock and 52,336 restricted stock units.
The footnotes state that each restricted stock unit represents a contingent right to receive one share of USANA common stock and that the units vest 25% annually on the specified February anniversaries.
USANA Health Sciences director Timothy E. Wood reported equity transactions involving restricted stock units and common stock of USNA. On January 22, 2026, 1,058 restricted stock units were converted into an equal number of shares of common stock at an exercise price of $0, increasing his directly held common shares to 10,085.
On the same date, he disposed of 265 shares of common stock at a price of $22.51 per share, leaving 9,820 common shares held directly after the reported transactions. Following the RSU conversion, he reported 1,057 restricted stock units beneficially owned. The filing notes that each restricted stock unit represents a contingent right to receive one share of USNA common stock, with these RSUs vesting 25% on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences director Frederic J. Winssinger reported the vesting and conversion of 1,058 restricted stock units into an equal number of USANA common shares on January 22, 2026. These shares were acquired at a stated price of $0 per share, reflecting the nature of restricted stock units as equity awards rather than open‑market purchases.
After this transaction, Winssinger directly held 7,044 shares of USANA common stock and 1,057 restricted stock units. The footnotes explain that each restricted stock unit represents the right to receive one share of common stock, and that this RSU grant vests in four 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences director Nixon J. Scott reported an equity award transaction. On January 22, 2026, 1,058 restricted stock units (RSUs) were converted into 1,058 shares of USANA common stock at an exercise price of $0.00 per share, reflecting the nature of RSUs as stock-based compensation rather than a cash purchase.
After this transaction, Scott directly owned 8,756 shares of USANA common stock and 1,057 RSUs. The RSUs vest in four equal 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026, each representing the right to receive one share of USANA common stock when vested.
USANA Health Sciences director Peggie Pelosi reported equity transactions dated January 22, 2026. A block of 1,058 restricted stock units converted into 1,058 shares of common stock at an exercise price of $0, increasing her direct common share holdings. On the same date, she disposed of 669 shares of common stock at $22.51 per share, leaving 4,975 common shares directly owned. Following the conversion, she also held 1,057 restricted stock units, each representing a contingent right to receive one share of USANA common stock, with vesting in 25% increments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences (USNA) director Gilbert A. Fuller reported an equity award vesting and share issuance. On January 22, 2026, 1,058 restricted stock units (RSUs) were converted into 1,058 shares of USANA common stock at an exercise price of $0, reported with transaction code "M." Following this transaction, Fuller directly owned 1,058 shares of common stock and 1,057 RSUs.
The RSUs vest in four equal installments of 25% each on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026. Each RSU represents a contingent right to receive one share of USANA common stock, reflecting a standard director equity compensation structure.